Kaufman Jonathan H's Form 4 filing
Lipella Pharmaceuticals Inc. (LIPO) · filed Mar 19, 2024
- Accession no.
- 0001753926-24-000573
- Filed
- Mar 19, 2024
- Trade date
- Mar 15-19, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $45.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kaufman Jonathan HCIK 0001959250 | Director, Officer (See remarks below.), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 15, 2024 | Common Stock | AGrant or awardAcquired | +80,000 | $0.00 | $0 | 80,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Reflects the weighted average price of the shares purchased on the open market in multiple transactions on March 18, 2024 at prices ranging from $0.77 to $0.80 per share, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of such shares of Common Stock purchased at each separate price within such range.
Referenced by the price of 2 transactions in Table I.
- F5
Reflects the weighted average price of the shares of Common Stock purchased on the open market in multiple transactions on March 19, 2024 at prices ranging from $0.75 to $0.89 per share, inclusive.
Referenced by the price of 1 transaction in Table I.
Remarks
President, Chief Executive Officer, Secretary, Treasurer, and Chairman of the Board of Directors